At-home Leqembi is given as a once-weekly injection under the skin using the Leqembi IQLIK autoinjector. The maintenance dose is 360 milligrams, typically started only after 18 months of intravenous Leqembi treatment and after the prescribing clinician confirms that home dosing is appropriate. For example, a person who has completed the initial infusion phase may receive training so that the patient or a caregiver can administer the weekly injection in the abdomen or thigh.
The autoinjector changes where and how maintenance treatment is delivered, but it does not make Leqembi an unsupervised medication. Patients still need specialist follow-up, symptom monitoring, and any MRI scans their clinician orders because lecanemab can cause amyloid-related imaging abnormalities, commonly called ARIA. A caregiver should not give the first home dose, replace an infusion, or change the dosing day without instructions from the prescribing team.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How Is At-Home Leqembi Given With the Autoinjector?
- Weekly Autoinjector Dosing and the Maintenance-Treatment Requirement
- Preparing and Giving a Leqembi IQLIK Injection
- Caregiver Checklist for Safe At-Home Leqembi Use
- ARIA, Bleeding Risk, and Symptoms That Need Urgent Attention
- Injection-Site Reactions and Device Problems
- Follow-Up Care, MRI Monitoring, and Sharps Disposal
- Frequently Asked Questions
How Is At-Home Leqembi Given With the Autoinjector?
leqembi IQLIK contains lecanemab-irmb for subcutaneous injection, meaning the medicine goes into the fatty tissue beneath the skin rather than into a vein or muscle. The prescribed 360-milligram maintenance dose is administered once each week with a single-dose autoinjector. The device is intended to simplify administration, but the patient or caregiver must first receive instruction on preparing, placing, and using it correctly. The injection sites specified in the device instructions should be followed carefully, generally involving an appropriate area of the abdomen or thigh.
The site should be rotated from week to week and should not be bruised, red, tender, scarred, hardened, or otherwise damaged. For example, someone who used the right side of the abdomen last week might use the left thigh this week if both locations are permitted by the prescribing instructions. An intravenous infusion is administered by clinical staff and takes place in a medical setting, while an autoinjector can be used at home after training. That convenience comes with a tradeoff: a nurse is not automatically present to recognize an administration error or evaluate new symptoms. The patient and caregiver therefore need clear instructions about whom to call during and outside clinic hours.
Weekly Autoinjector Dosing and the Maintenance-Treatment Requirement
At-home autoinjector dosing is a maintenance option, not the standard starting treatment for every newly diagnosed patient. Under the approved maintenance regimen, a patient generally receives intravenous Leqembi every two weeks for 18 months before moving to 360 milligrams under the skin once weekly. The prescribing neurologist determines whether the transition is appropriate and when the first injection should occur. The medicine is used for Alzheimer’s disease in patients at the mild cognitive impairment or mild dementia stage, the population in which treatment was studied, and amyloid pathology should be confirmed before treatment begins.
It is not intended for every cause or stage of dementia. A person with advanced Alzheimer’s disease, vascular dementia without confirmed Alzheimer’s amyloid, or an uncertain diagnosis should not assume that an autoinjector prescription is appropriate. Weekly treatment requires a dependable calendar system. A caregiver might record each dose in a medication log immediately after administration and set a reminder for the same day the following week. If a dose is missed, delayed, leaked, or may not have been delivered completely, the caregiver should follow the prescribing information and contact the treatment team rather than giving an extra dose to compensate.
Preparing and Giving a Leqembi IQLIK Injection
Before each injection, the caregiver should confirm the patient’s name, the medication, the prescribed dose, the expiration date, and the planned injection day. The autoinjector should be removed from refrigerated storage and prepared exactly as described in its Instructions for Use. It should not be shaken, frozen, heated with hot water, microwaved, or left where children or cognitively impaired household members can access it. The medicine and device should be inspected as the instructions direct.
Do not use an autoinjector that is expired, damaged, previously used, frozen, or visibly abnormal. If the device has been dropped or the medicine’s appearance raises concern, call the pharmacy or treatment center for guidance; attempting to repair or test-fire the injector can waste the dose or cause an accidental needle injury. During administration, place the device against an approved injection site and keep it in position for the full delivery sequence described in the device instructions. A practical approach is for the caregiver to read the indicator and completion instructions before starting, not while the injection is already underway. Afterward, apply gentle pressure with clean gauze if needed, but do not rub the area aggressively because that can worsen irritation or bruising.
Caregiver Checklist for Safe At-Home Leqembi Use
A written dosing record should include the date, time, injection site, device completion indicator, and any reaction. This is more reliable than memory alone, especially when several relatives share caregiving duties. For example, if a daughter gives Monday’s injection, documenting it immediately prevents a second caregiver from mistakenly repeating the dose on Tuesday. Store unused autoinjectors in their original carton in the refrigerator, protected from light, and follow the labeled temperature requirements.
Do not freeze or shake them. If a device has been left out, exposed to heat, or stored incorrectly, ask the dispensing pharmacy whether it remains usable rather than returning it to the refrigerator and assuming it is safe. Home dosing reduces regular trips to an infusion center, but it shifts several responsibilities to the household: correct storage, dose tracking, injection technique, sharps disposal, and symptom recognition. A caregiver who has poor vision, hand weakness, severe tremor, or difficulty understanding the device indicators may need another trained person to administer the medicine or may find clinic-based treatment safer.
ARIA, Bleeding Risk, and Symptoms That Need Urgent Attention
Leqembi can cause ARIA, which may appear as temporary brain swelling or small areas of bleeding on MRI. Many cases produce no obvious symptoms, but serious and occasionally fatal events have occurred. Possible symptoms include headache, confusion, dizziness, vision changes, nausea, difficulty walking, weakness, numbness, seizures, or a sudden change in behavior or alertness. New neurological symptoms should not be dismissed as ordinary dementia progression or an injection side effect.
For example, if a patient becomes unusually confused and develops one-sided weakness several hours after a dose, the caregiver should seek emergency evaluation and tell clinicians that the patient receives lecanemab. The treatment team may order an urgent MRI and may pause dosing depending on the findings and symptom severity. Risk is higher in some patients, including people with two copies of the APOE ε4 gene. Clinicians may recommend genetic testing and counseling when discussing ARIA risk. Blood thinners, antiplatelet medicines, clot-dissolving drugs, bleeding disorders, and certain MRI findings also require careful review; caregivers should never stop a prescribed cardiovascular medicine on their own, but every treating clinician should know that the patient receives Leqembi.
Injection-Site Reactions and Device Problems
Redness, swelling, itching, tenderness, or discomfort can occur where the autoinjector was used. A caregiver can photograph a reaction next to a ruler and note when it began so the clinic can assess whether it is improving.
Spreading redness, severe swelling, blistering, breathing difficulty, facial swelling, widespread hives, or faintness requires prompt medical attention. If the device is removed too soon, leaks substantially, fails to activate, or does not show the expected completion signal, do not reuse it or immediately inject another dose. Keep the device available if the pharmacy or manufacturer needs identifying information, place it safely away from others, and contact the treatment team for dose-specific instructions.
Follow-Up Care, MRI Monitoring, and Sharps Disposal
Switching to home injections does not end neurological follow-up. The clinician may continue cognitive assessments, medication reviews, MRI monitoring, and discussions about treatment benefit, ARIA, and changes in overall health. A patient who falls, starts an anticoagulant, develops stroke-like symptoms, or receives a new diagnosis affecting bleeding risk should have that information communicated promptly to the Leqembi prescriber.
Used autoinjectors belong in an FDA-cleared sharps container, not loose in household trash or recycling. If a commercial container is unavailable, local rules may permit a heavy-duty, puncture-resistant plastic container with a secure lid, but disposal requirements vary. For example, some communities accept sealed containers at pharmacies or household hazardous-waste sites, while others require a designated medical-sharps collection program.
Frequently Asked Questions
Can a person begin Leqembi treatment with the home autoinjector?
The at-home autoinjector is approved for maintenance treatment after the required intravenous treatment period. A neurologist should determine eligibility and the timing of the transition.
How often is at-home Leqembi given?
The approved maintenance dose is 360 milligrams injected under the skin once weekly.
Can a caregiver give the injection?
A trained caregiver may administer it when the prescribing team considers home treatment appropriate. The caregiver should be able to store the device correctly, follow its indicators, maintain dosing records, and recognize urgent symptoms.
What should a caregiver do after a missed or incomplete dose?
Do not double the dose or use a second autoinjector without instructions. Contact the prescribing clinic or dispensing pharmacy and follow the current prescribing information.
Are MRIs still needed after switching to home injections?
They may be. The clinician determines MRI monitoring based on the treatment schedule, earlier imaging, symptoms, genetic risk, and other medical factors. New neurological symptoms can require an unscheduled MRI.
Is sudden confusion simply an expected Alzheimer’s symptom?
Not necessarily. Sudden confusion, weakness, vision changes, severe headache, seizures, or difficulty walking can indicate ARIA, stroke, or another emergency and should be evaluated promptly.
